Financials • Investment Bankers/Brokers/Service
$296.42 ▲ +2.38
(+0.81%)
MKT CAP: $106.10B • VOL: 2.20M
52W L $218 52W H $329
CME // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $6.52B | $6.13B | $5.58B |
| YoY Revenue Growth % | +6.4% | +9.9% | — |
| Gross Profit | $2.87B | $2.70B | $2.45B |
| Gross Margin % | 44.0% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $4.23B | $3.93B | $3.44B |
| Operating Margin % | 64.9% | 64.1% | 61.6% |
| Net Income (GAAP) | $4.07B | $3.53B | $3.23B |
| EBITDA (Normalized) | $4.30B | $4.01B | $3.64B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $4.28B | $3.69B | $3.45B |
| Capital Expenditures (CapEx) | $83.5M | $94.0M | $251.1M |
| Free Cash Flow (FCF) | $4.19B | $3.60B | $3.20B |
| FCF Margin % | 64.3% | 58.7% | 57.4% |
| Return on Invested Capital (ROIC %) | 3.3% | 4.2% | 7.7% |
| Cash & Short-Term Equivalents | $4.42B | $2.89B | $6.42B |
| Total Debt (Short + Long Term) | $76.36B | $49.93B | $13.65B |
| Total Stockholders' Equity | $28.73B | $26.49B | $28.01B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CME.